[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640974":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":220,"collaborators":26,"id":222,"slug":223,"hasResults":224,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":224,"sex":230,"minAge":231,"maxAge":232,"enrollmentInfo":233,"targetDuration":26,"studyType":236,"phases":237,"briefSummary":239,"conditions":240,"keywords":242,"overallStatus":74,"whyStopped":26,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":257},{"fullName":5,"class":6},"Sun Pharma Japan Limited","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Deuruxolitinib 8 mg","EXPERIMENTAL","Participants in this arm will receive deuruxolitinib 8 mg administered orally twice daily (BID) during the 24-week double-blind treatment period and continue to receive deuruxolitinib 8 mg administered orally BID up to 52 weeks",[13],"Drug: Deuruxolitinib",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants in this arm will receive matching placebo administered orally BID during the 24-week double-blind treatment period and then receive deuruxolitinib 8 mg administered orally BID up to 52 weeks.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Deuruxolitinib","Deuruxolitinib will be dosed orally as tablets at a dose of 8 mg",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":30},"Deuruxolitinib matching placebo will be dosed orally as tablets for up to 24 weeks and then deuruxolitinib will be dosed for up to 52 weeks",[15],[23],[32,45,54,63,72,88,101,110,119,128,137,145,149,162,175,185,198,207],{"facility":33,"status":34,"city":35,"state":26,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":26},"Study Site 102","NOT_YET_RECRUITING","Asahikawa","078-8510","Japan","JP",{"type":40,"coordinates":41},"Point",[42,43],142.36489,43.77063,{"lat":43,"lon":42},{"facility":46,"status":34,"city":47,"state":26,"zip":48,"country":37,"countryCode":38,"cosmosGeoPoint":49,"geoPoint":53,"contacts":26},"Study Site 117","Bunkyō City","113-8431",{"type":40,"coordinates":50},[51,52],139.4217,35.5331,{"lat":52,"lon":51},{"facility":55,"status":34,"city":56,"state":26,"zip":57,"country":37,"countryCode":38,"cosmosGeoPoint":58,"geoPoint":62,"contacts":26},"Study Site 119","Ebina","243-0432",{"type":40,"coordinates":59},[60,61],139.39651,35.38121,{"lat":61,"lon":60},{"facility":64,"status":34,"city":65,"state":26,"zip":66,"country":37,"countryCode":38,"cosmosGeoPoint":67,"geoPoint":71,"contacts":26},"Study Site 101","Hamamatsu","431-3192",{"type":40,"coordinates":68},[69,70],137.73333,34.7,{"lat":70,"lon":69},{"facility":73,"status":74,"city":75,"state":26,"zip":76,"country":37,"countryCode":38,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Study Site 116","RECRUITING","Ishikawa","920-0293",{"type":40,"coordinates":78},[79,80],127.82139,26.42333,{"lat":80,"lon":79},[83],{"name":84,"role":85,"phone":86,"phoneExt":26,"email":87},"Aikawa","CONTACT","+81-76-218-8346","JPS.clinicaltrial@sunpharma.com",{"facility":89,"status":74,"city":90,"state":26,"zip":91,"country":37,"countryCode":38,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Study Site 112","Kitakyushu","807-8556",{"type":40,"coordinates":93},[94,95],130.85034,33.85181,{"lat":95,"lon":94},[98],{"name":99,"role":85,"phone":100,"phoneExt":26,"email":87},"Kitamura","+81-93-691-7503",{"facility":102,"status":34,"city":103,"state":26,"zip":104,"country":37,"countryCode":38,"cosmosGeoPoint":105,"geoPoint":109,"contacts":26},"Study Site 118","Kōtoku","136-0075",{"type":40,"coordinates":106},[107,108],143.14297,42.50417,{"lat":108,"lon":107},{"facility":111,"status":34,"city":112,"state":26,"zip":113,"country":37,"countryCode":38,"cosmosGeoPoint":114,"geoPoint":118,"contacts":26},"Study Site 110","Kurashiki","701-0192",{"type":40,"coordinates":115},[116,117],133.76667,34.58333,{"lat":117,"lon":116},{"facility":120,"status":34,"city":121,"state":26,"zip":122,"country":37,"countryCode":38,"cosmosGeoPoint":123,"geoPoint":127,"contacts":26},"Study Site 113","Kurume","830-0011",{"type":40,"coordinates":124},[125,126],130.51667,33.31667,{"lat":126,"lon":125},{"facility":129,"status":34,"city":130,"state":26,"zip":131,"country":37,"countryCode":38,"cosmosGeoPoint":132,"geoPoint":136,"contacts":26},"Study Site 107","Kyoto","606-8507",{"type":40,"coordinates":133},[134,135],135.75385,35.02107,{"lat":135,"lon":134},{"facility":138,"status":74,"city":139,"state":26,"zip":140,"country":37,"countryCode":38,"cosmosGeoPoint":26,"geoPoint":26,"contacts":141},"Study Site 106","Mitaka-shi","181-8611",[142],{"name":143,"role":85,"phone":144,"phoneExt":26,"email":87},"Nakada","+81-422-47-5511",{"facility":146,"status":34,"city":147,"state":26,"zip":148,"country":37,"countryCode":38,"cosmosGeoPoint":26,"geoPoint":26,"contacts":26},"Study Site 114","Miyagi-gun","981-0112",{"facility":150,"status":74,"city":151,"state":26,"zip":152,"country":37,"countryCode":38,"cosmosGeoPoint":153,"geoPoint":157,"contacts":158},"Study Site 104","Niigata","951-8520",{"type":40,"coordinates":154},[155,156],139.04125,37.92259,{"lat":156,"lon":155},[159],{"name":160,"role":85,"phone":161,"phoneExt":26,"email":87},"Clinical Trial Office, Center for Clinical Research","+81-25-227-2436",{"facility":163,"status":74,"city":164,"state":26,"zip":165,"country":37,"countryCode":38,"cosmosGeoPoint":166,"geoPoint":170,"contacts":171},"Study Site 109","Osaka","542-0081",{"type":40,"coordinates":167},[168,169],135.50107,34.69379,{"lat":169,"lon":168},[172],{"name":173,"role":85,"phone":174,"phoneExt":26,"email":87},"Medical System Research Institute Co., Ltd.","+81-6-6484-5755",{"facility":176,"status":74,"city":164,"state":26,"zip":177,"country":37,"countryCode":38,"cosmosGeoPoint":178,"geoPoint":180,"contacts":181},"Study Site 108","545-0051",{"type":40,"coordinates":179},[168,169],{"lat":169,"lon":168},[182],{"name":183,"role":85,"phone":184,"phoneExt":26,"email":87},"Clinical Trial Office, Clinical Research and Innovation Center","+81-06-6645-2121",{"facility":186,"status":74,"city":187,"state":26,"zip":188,"country":37,"countryCode":38,"cosmosGeoPoint":189,"geoPoint":193,"contacts":194},"Study Site 103","Sapporo","060-8648",{"type":40,"coordinates":190},[191,192],141.35,43.06667,{"lat":192,"lon":191},[195],{"name":196,"role":85,"phone":197,"phoneExt":26,"email":87},"Hashimoto","+81-11-706-7061",{"facility":199,"status":74,"city":200,"state":26,"zip":201,"country":37,"countryCode":38,"cosmosGeoPoint":26,"geoPoint":26,"contacts":202},"Study Site 105","Shinjuku-Ku","160-0023",[203],{"name":204,"role":85,"phone":205,"phoneExt":206,"email":87},"Nakayama","+81-3-3342-6111","3951",{"facility":208,"status":74,"city":209,"state":26,"zip":210,"country":37,"countryCode":38,"cosmosGeoPoint":211,"geoPoint":215,"contacts":216},"Study Site 111","Ube","755-8505",{"type":40,"coordinates":212},[213,214],131.25111,33.94306,{"lat":214,"lon":213},[217],{"name":218,"role":85,"phone":219,"phoneExt":26,"email":87},"Clinical Research Center, Clinical Trial Office","+81-836-85-3030",{"type":221,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100640974","phase-3-study-to-evaluate-the-efficacy-and-safety-of-deuruxolitinib-in-japanese-adults-with-severe-alopecia-areata-100640974",false,"NCT07617597","Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Japanese Adults With Severe Alopecia Areata","A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adult Patients With Severe Alopecia Areata With an Open-Label Extension Period","THRIVE-AAJP","Inclusion Criteria:\n\n* Written informed consent has been obtained.\n* Japanese subjects with severe alopecia areata who are between 18 and 65 years of age, inclusive, at the time of informed consent.\n* Definitive diagnosis of alopecia areata with a current episode of scalp hair loss lasting at least 6 months.\n* SALT score of 50 or more at both Screening and Baseline.\n\nExclusion Criteria:\n\n* Treatment with systemic immunosuppressive medications or agents, including Janus kinase inhibitors, within 4 months prior to randomization.\n* Treatment with biologics within 6 months prior to Screening.\n* Positive test results for hepatitis B virus, hepatitis C virus, or human immunodeficiency virus at Screening.\n* History of active tuberculosis, a positive interferon gamma release assay at Screening, or evidence of tuberculosis-related lesions on chest radiography.\n* Clinically significant hematologic abnormalities, hepatic impairment, or renal impairment at Screening.","ALL","18 Years","65 Years",{"count":234,"type":235},78,"ESTIMATED","INTERVENTIONAL",[238],"PHASE3","This study evaluates the efficacy and safety of deuruxolitinib in Japanese Adults between 18 and 65 years of age who have 50% or greater scalp hair loss.",[241],"Alopecia Areata",[243,244,245,246,247],"alopecia areata","severe alopecia areata","hair loss","deuruxolitinib","JAK inhibitor","2026-08-17",{"date":250,"type":251},"2026-08-18","ACTUAL",{"date":253,"type":251},"2026-06-19",{"date":255,"type":235},"2028-09",{"name":5,"class":6},18]